Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2015	Nov. 02, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,806,903

Condensed Balance Sheets (USD $)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 12,541,919	$ 5,364,582
Accounts receivable	40,360	10,600
Inventories, net	302,005	188,728
Prepaid expenses and other current assets	456,894	338,721
Total current assets	13,341,178	5,902,631
Fixed assets, net	855,208	662,422
Total assets	14,196,386	6,565,053
Current liabilities:
Accounts payable	766,436	641,406
Accrued liabilities	916,730	699,903
Supplier financings		33,674
Current portion of equipment financings	125,920	55,800
Current portion of credit facility	1,556,909
Current portion of deferred rent	24,752
Total current liabilities	3,390,747	1,430,783
Non-current portion of equipment financings, net	244,612	68,801
Non-current portion of credit facility, net	3,020,166	4,731,322
Non-current portion of interest payable	131,543	54,537
Non-current portion of deferred rent	481,041	500,179
Total liabilities	7,268,109	6,785,622
Commitments and contingencies (see Note 10)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 4,449,603 issued and outstanding at December 31, 2014; 18,766,903 issued and outstanding at September 30, 2015 (see Note 2)	1,877	445
Additional paid-in capital	157,545,448	138,066,008
Accumulated deficit	(150,619,048)	(138,287,022)
Total shareholders’ equity/(deficit)	6,928,277	(220,569)
Total liabilities and shareholders’ equity/(deficit)	$ 14,196,386	$ 6,565,053

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	18,766,903	4,449,603
Common stock, shares outstanding	18,766,903	4,449,603

Condensed Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenues:	$ 164,856	$ 10,274	$ 391,626	$ 57,794
Costs and expenses:
Cost of revenues	1,159,710	538,181	3,320,467	1,555,861
Research and development expenses	677,729	1,310,905	2,073,391	3,427,513
General and administrative expenses	1,630,608	1,060,812	4,281,883	3,970,579
Sales and marketing expenses	1,055,653	812,005	2,616,218	1,246,507
Total costs and expenses	4,523,700	3,721,903	12,291,959	10,200,460
Loss from operations	(4,358,844)	(3,711,629)	(11,900,333)	(10,142,666)
Other income/(expense):
Interest expense, net	(176,120)	(151,491)	(494,596)	(1,640,045)
Change in fair value of warrant liability	558	3,326	361	(200,994)
Other income	38,412		64,020
Total other income/(expense):	(137,150)	(148,165)	(430,215)	(1,841,039)
Loss before income taxes	(4,495,994)	(3,859,794)	(12,330,548)	(11,983,705)
Income tax expense	(199)		(1,478)	(800)
Net loss & comprehensive loss	$ (4,496,193)	$ (3,859,794)	$ (12,332,026)	$ (11,984,505)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	18,727,806	4,449,603	15,735,907	3,845,540
Diluted	18,727,806	4,449,603	15,735,907	3,845,540
Net loss per common share:
Basic	$ (0.24)	$ (0.87)	$ (0.78)	$ (3.12)
Diluted	$ (0.24)	$ (0.87)	$ (0.78)	$ (3.12)

Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
Condensed Statements of Cash Flows (Unaudited) (USD $)	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (12,332,026)	$ (11,984,505)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	188,120	177,516
Inventory reserve	(20,277)	(9,616)
Stock-based compensation	1,016,266	1,506,586
Non-cash interest expense related to convertible debt, credit facility and other financing activities	93,454	1,428,324
Change in fair value of warrant liability	(361)	200,994
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(29,760)	(3,245)
Inventory	(93,000)	(46,201)
Prepaid expenses and other current assets	(181,284)	(528,988)
Other non-current assets		500
Accounts payable	142,028	(992,399)
Accrued liabilities	218,829	(1,177,510)
Accrued interest	96,295	38,304
Deferred rent	5,614	33,238
Net cash used in operating activities	(10,896,102)	(11,357,002)
Cash Flows From Investing Activities:
Purchases of fixed assets	(118,896)	(201,835)
Net cash used in investing activities	(118,896)	(201,835)
Cash Flows From Financing Activities:
Net proceeds from issuance of common stock	8,830,057	17,390,240
Proceeds from exercise of common stock warrants	9,697,660
Payments on equipment financings	(54,007)	(9,300)
Payments on supplier and other third party financings	(33,674)	(163,411)
Payments on line of credit	(247,701)	(2,346,000)
Proceeds from borrowings on line of credit		365,000
Proceeds from issuance of convertible notes and warrants		175,000
Net proceeds from borrowings on credit facility and warrants		4,898,002
Net cash provided by financing activities	18,192,335	20,309,531
Net increase in Cash and Cash Equivalents	7,177,337	8,750,694
Cash and Cash Equivalents at Beginning of Period	5,364,582	69,178
Cash and Cash Equivalents at End of Period	12,541,919	8,819,872
Cash paid during the period for:
Interest	309,324	298,381
Taxes	$ 2,054	$ 800

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	0 Months Ended	9 Months Ended
	Feb. 10, 2014	Sep. 30, 2015	Sep. 30, 2014
Cancellation of insurance premiums amount, other			$ 44,559
Cancellation of insurance premiums partial amount received			10,955
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings			135,222
Overallotment issued to underwriter to purchase common stock, period	45 days	45 days
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 9.30
Purchase of common stock by underwriters to cover overallotments, grant date fair value		7,690,395
Warrants to purchase common stock, period	5 years	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		1,627,396
Underwriter IPO costs	279,760
Underwriter discount from initial public offering	1,330,000
Deferred offering costs classified to additional paid in capital	932,136
Warrants reclassified to additional paid-in capital	2,500,000
Conversion price of notes	$ 10.00
Common shares issuable to underwriters under granted option		1,200,000
Common Shares issuable to underwriters under warrants granted		1,200,000
Common stock, par value		$ 0.0001
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs		63,111
Purchases of fixed assets		3,190	4,775
Fixed assets purchased under capital lease obligations		279,008	140,267
April 2014 Credit Facility [Member]
Issuance of warrants to purchase shares of common stock, grant date fair value			233,107
Aegis Capital Corp
Purchase of common stock by underwriters to cover overallotments, grant date fair value	202,143
Issuance of warrants to purchase shares of common stock	95,000
Exercise price of warrants	$ 12.50
Issuance of warrants to purchase shares of common stock, grant date fair value	544,116
2008 Convertible Note [Member]
Debt, principal amount converted	1,400,000
Conversion price of notes	$ 10.00
Convertible Bridge Notes And Line Of Credit [Member]
Exercise price of warrants	$ 10.00
Warrants reclassified to additional paid-in capital	2,475,620
Warrants reclassified to additional paid-in capital	387,152
2013 Convertible Bridge Notes [Member]
Exercise price of warrants	$ 10.00
Debt, principal amount converted	5,165,000
Accrued interest on convertible debt converted	313,017
Conversion price of notes	$ 10.00
Convertible Note converted into preferred/common stock	548,803
Warrants reclassified to additional paid-in capital	258,249
Common Stock [Member] \| 2008 Convertible Note [Member]
Convertible Note converted into preferred/common stock	163,399
Common Stock [Member] \| 2013 Convertible Bridge Notes [Member]
Convertible Note converted into preferred/common stock	547,794
Accrued interest [Member] \| 2008 Convertible Note [Member]
Accrued interest on convertible debt converted	233,982
Accrued interest [Member] \| 2013 Convertible Bridge Notes [Member]
Accrued interest on convertible debt converted	$ 300,000

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2014, filed with the SEC with our Annual Report on Form 10-K on March 11, 2015 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $318,565 of revenue-generating costs previously allocated to research and development expenses during the six months ended June 30, 2015 were reclassified to cost of revenues in the current period presentation of the unaudited condensed statement of operations and comprehensive loss for the nine months ended September 30, 2015. The Company and Business Activities Biocept, Inc. (the “Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (“CTC”) and circulating tumor DNA (“ctDNA”) assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures Cell Enrichment and Extraction (“CEE”) microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, the Financial Standards Accounting Board (the “FASB”) issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In April 2015, the FASB issued authoritative guidance requiring debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability. This guidance is effective on a retrospective basis for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company early adopted this guidance on a retrospective basis for the interim reporting period ended March 31, 2015. A balance of $23,194 of such costs were reclassified from other non-current assets, net to non-current portion of credit facility, net in the Company’s balance sheet as of December 31, 2014. A total of $15,093 of such costs remain unamortized and recorded as an offset to non-current portion of credit facility, net in the Company’s unaudited condensed balance sheet at September 30, 2015. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In August 2015, the FASB issued amendments to SEC paragraphs referenced in authoritative guidance around the presentation and subsequent measurement of debt issuance costs associated with line-of-credit arrangements. These amendments state that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company’s adoption of these amendments upon issuance did not have a material impact on its financial statements or disclosures.

Public Offerings	9 Months Ended
Public Offerings	Sep. 30, 2015
Equity [Abstract]
Public Offerings	2. Public Offerings Pursuant to an underwriting agreement dated February 4, 2014 between the Company and Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein, an IPO of 1,900,000 shares of common stock at $10.00 per share was effected on February 5, 2014. The closing of the sale of these shares to the underwriters occurred on February 10, 2014. The Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $17.4 million of net cash proceeds from the sale of these 1,900,000 shares. The total increase in capital as a result of the sale of these shares was $16.5 million after deducting $0.9 million of additional non-underwriter costs incurred that were netted against these proceeds under applicable accounting guidance. Additionally, the underwriters were granted a 45 day option from the closing date of the IPO to purchase up to 285,000 shares of common stock at $9.30 per share to cover overallotments with an estimated grant date fair value of $0.2 million, which was not exercised. In addition, designees of Aegis were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock at $12.50 per share with a term of five years and an estimated grant date fair value of $0.5 million. On February 4, 2014, as contemplated by the registration statement covering the IPO, 69,421,047 shares of outstanding Series A Convertible Preferred Stock with a par value of $0.0001 per share were converted into 1,652,851 shares of common stock and the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock. There were no shares of preferred stock issued or outstanding as of December 31, 2014 or September 30, 2015. In connection with the closing of the IPO on February 10, 2014, (i) the $1.4 million principal amount and $0.2 million of accrued interest related to the convertible note issued in 2008 were converted at $10.00 per share into a total of 163,399 shares of common stock, (ii) the $5.2 million principal amount and $0.3 million of accrued interest related to the convertible notes issued in 2013 were converted at $10.00 per share into a total of 547,794 shares of common stock, (iii) the exercise price of the warrants associated with the convertible notes issued in 2013 was fixed at $10.00 per share for an aggregate 258,249 shares of common stock, (iv) the exercise price of the warrants associated with the $2.6 million of collateral provided to secure the Company’s line of credit was fixed at $10.00 per share for an aggregate 128,903 shares of common stock, (v) 73,151 shares of common stock vested as settlement of certain restricted stock units (which were previously expressed in shares of preferred stock) and became issuable subsequent to the expiration of the 180 day lock-up period following the IPO, (vi) the Company’s Executive Chairman ceased to be an employee and continues to serve as non-executive Chairman, (vii) the number of shares of common stock covered by the Company’s 2013 Equity Incentive Plan increased by 800,000, (viii) all but 1,587 of the preferred warrants previously outstanding were canceled due to early termination clauses associated with the IPO, (ix) derivative warrant liabilities of $2.5 million associated with the aggregate of 387,152 common stock warrants related to the convertible notes issued in 2013 and line of credit were reclassified to additional paid-in capital when their underlying exercise price was fixed, (x) unamortized discounts of $1.0 million related to the warrants associated with the convertible notes issued in 2013 and line of credit were reclassified to interest expense, and (xi) offering costs associated with the IPO of $0.9 million were reclassified from prepaid expenses and other current assets to additional paid-in capital, while additional underwriter IPO costs and discounts of $0.3 million and $1.3 million, respectively, were netted against the proceeds from the IPO and are reflected as an offset to additional paid-in capital. Subsequent to December 31, 2013, the maximum amount of the Company’s line of credit was increased to approximately $2.6 million and common stock warrants were issued to four shareholders in conjunction with their guarantees on the Company’s additional borrowings under the line of credit. On February 10, 2014, the current outstanding balance under the line of credit of approximately $2.3 million plus accrued interest of $27,043 was paid in full using the net proceeds from the IPO. On February 13, 2014, the Compensation Committee of the Company’s Board of Directors approved payments of approximately $1.0 million for deferred salary obligations, including contractual interest, to current and former executive officers pursuant to previously existing agreements, which was fully disbursed by April 2014 using the net proceeds from the IPO. An additional $344,883 in deferred salary obligations and interest thereon was paid to former employees other than executive officers. Also on February 13, 2014, in connection with the closing of the IPO and pursuant to a director compensation policy adopted by the Company’s Board of Directors in 2013, the Company’s Board of Directors approved annual cash retainers to non-employee directors, and granted 238,500 stock options under the Company’s 2013 Equity Incentive Plan to non-employee directors. These option awards vest in equal annual installments over 3 years from the date of grant with a 10 year term, subject to continuing service requirements. Subsequently in February 2014, the Company’s Board of Directors approved grants of 54,298 stock options as a result of the closing of the IPO pursuant to the terms of underlying employment agreements. Included in the stock options granted pursuant to the terms of underlying employment agreements were 53,108 option awards granted to the Company’s non-executive Chairman, which vested fully on the date of grant. Under the terms of certain employment agreements with executive officers, the Company incurred additional cash compensation expense of $150,000 immediately, and $225,000 annually, upon the closing of its IPO. All payments required under these agreements as a result of the closing of the IPO on February 10, 2014 were subsequently made in February and March 2014, using the net proceeds from the IPO. During the year ended December 31, 2014, the Company repaid in full the remaining amounts outstanding of approximately $70,000 due for laboratory equipment under financing agreements with a supplier, which is a business owned by a member of the Company’s board of directors, using the net proceeds from the IPO. Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering (see Note 4). Each of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for a total purchase price of $177,500. All warrants sold in this offering have a per share exercise price of $1.56, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 million after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any, which was not exercised. The estimated grant date fair value of the over-allotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering (see Note 4). Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional non-underwriter costs associated with the offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015 and through November 2, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting $0.9 million of underwriter costs and discounts and $0.3 million of additional non-underwriter costs incurred, which were netted against these proceeds under applicable accounting guidance.

Liquidity and Going Concern Uncertainty	9 Months Ended
Liquidity and Going Concern Uncertainty	Sep. 30, 2015
Cash And Cash Equivalents [Abstract]
Liquidity and Going Concern Uncertainty	3. Liquidity & Going Concern Uncertainty These unaudited condensed financial statements have been prepared and presented on a basis assuming the Company will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At December 31, 2014 and September 30, 2015, the Company had accumulated deficits of $138.3 million and $150.6 million, respectively. For the year and nine month periods ended December 31, 2014 and September 30, 2015, the Company incurred net losses of $15.9 million and $12.3 million, respectively. The Company borrowed a total of $0.5 million during the year ended December 31, 2014 under note agreements with certain shareholders and a line of credit. In addition, the Company borrowed $5.0 million during the year ended December 31, 2014 under a credit facility entered into in April 2014. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from clinical laboratory testing through contracted partners. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant net revenues to achieve and sustain income from operations. As of September 30, 2015, cash and cash equivalents totaled $12.5 million. On February 13, 2015, the Company received net cash proceeds of $9.1 million as a result of the closing of a follow-on public offering, before deducting $0.3 million of additional non-underwriting costs incurred. Subsequent to the closing of the follow-on public offering on February 13, 2015 and through November 2, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. Management expects that the Company will need additional financing in the future to execute on its current or future business strategies beyond June 2016. Until the Company can generate significant cash from operations, including assay revenues, the Company expects to continue to fund its operations with the proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. As of September 30, 2015, the Company had not sold any securities under this shelf registration statement. The specific terms of future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

Fair Value Measurement

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurement

4. Fair Value Measurement

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, other than warrant liability, approximate their estimated fair values due to the short-term maturities of these financial instruments. The estimated fair value of the Company’s credit facility at September 30, 2015 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

In connection with the closing of the Company’s public offering on February 13, 2015, warrants were issued to buy (in the aggregate) up to 8,000,000 shares of common stock with an estimated grant date fair value of $7,690,395, which was recorded as an offset to additional paid-in capital within common stock issuance costs. Also in connection with the closing of the Company’s follow-on public offering on February 13, 2015, the underwriters were granted a 45 day option from the closing date of the offering to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any. The estimated aggregate grant date fair value of these over-allotment options and warrants of $1,627,396 was also recorded to common stock issuance costs as a component of additional paid-in capital. The fair values of these over-allotment options and all common stock warrants issued in this offering were estimated using Black-Scholes valuation models with the following assumptions:

	Over-allotment Options			Warrants
Stock price	$	1.41		$	1.41
Exercise price	$	1.25		$	1.56
Expected dividend yield		0.00	%		0.00	%
Discount rate-bond equivalent yield		0.02	%		1.53	%
Expected life (in years)		0.12			5.00
Expected volatility		168.1	%		90.0	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Balance Sheet Details

9 Months Ended

Sep. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Details

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,		September 30,
	2014		2015
Fixed Assets
Machinery and equipment	$	2,922,303	$	2,997,676
Furniture and office equipment		209,844		212,659
Computer equipment and software		681,508		756,365
Leasehold improvements		506,328		514,614
Financed equipment		878,447		1,157,455
Construction in process		72,172		12,739
		5,270,602		5,651,508
Less accumulated depreciation and amortization		4,608,180		4,796,300
Total fixed assets, net	$	662,422	$	855,208
Accrued Liabilities
Accrued interest	$	33,125	$	31,484
Accrued payroll		82,241		216,154
Accrued vacation		276,574		286,125
Accrued bonuses		302,763		286,557
Accrued sales commissions		—		63,167
Warrant liability		1,070		709
Other		4,130		32,534
Total accrued liabilities	$	699,903	$	916,730

April 2014 Credit Facility	9 Months Ended
April 2014 Credit Facility	Sep. 30, 2015
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,927,000 pursuant to the execution of its April 2014 Credit Facility with Oxford Finance LLC. A second term loan of up to a principal amount of $5 million will be funded at the Company’s request prior to December 31, 2015, subject to the achievement of product and services revenues of at least $9 million for the trailing six months, with such six-month period ending no later than November 30, 2015. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lenders a facility fee of $50,000 in conjunction with the funding of the first term loan. Another $50,000 facility fee will be due and payable to the lenders on the funding date of the second term loan (if such date occurs). The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Each term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the applicable term loan, plus (b) 7.71%, such rate to be fixed at the time of borrowing. The first term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the first term loan through August 1, 2015. If the Company requests and the lenders fund the second term loan, the Company is required to make interest-only payments on the second term loan through the seventh month following the funding date of the second term loan. All outstanding term loans under the April 2014 Credit Facility will begin amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lenders in consecutive monthly installments following such interest-only period. The first term loan under the April 2014 Credit Facility matures on July 1, 2018, and the second term loan matures on the first day of the 29th month following the end of the applicable interest-only period. Upon repayment of each term loan, the Company is also required to make a final payment to the lenders equal to 5.5% of the original principal amount of such term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loans in whole but not in part, subject to a prepayment fee of 2% of the amount prepaid if the prepayment occurs prior to April 30, 2016, and 1% of any amount prepaid after April 30, 2016. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries the Company creates in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on the Company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loans under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, the Company’s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. Additional warrants to purchase shares of the Company’s common stock will be issued upon execution of the second term loan under the April 2014 Credit Facility in an amount equal to 5.0% of the funded amount divided by the exercise price, which will be equal to the lower of (i) the closing price per share of the Company’s common stock on the NASDAQ on the date prior to the funding date of the second term loan or (ii) the ten-day average closing price per share prior to the funding date of the second term loan. The effective annual interest rate associated with the April 2014 Credit Facility was 10.81% at December 31, 2014 and 11.50% at September 30, 2015.

Stock-based Compensation

9 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

7. Stock-based Compensation

Equity Incentive Plans

On January 1, 2015, the number of shares of common stock covered by the Company’s 2013 Equity Incentive Plan automatically increased by 222,480 shares, or 5% of the number of common shares then outstanding, to a total of 1,426,051 shares. At the Company’s annual meeting of stockholders held on June 16, 2015, the stockholders approved the Company’s Amended and Restated 2013 Equity Incentive Plan (“2013 Plan”), which included (i) an increase in the number of shares of common stock authorized for issuance under the 2013 Plan by 1,500,000 shares, and (ii) a provision that shares available for grant under the Company’s 2007 Equity Incentive Plan (“2007 Plan”) become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. As of September 30, 2015, under all plans, a total of 3,104,622 shares were authorized for issuance, 2,131,603 stock options and restricted stock units (“RSUs”) had been issued and were outstanding, and 836,082 shares were available for grant.

Stock Options

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2015 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Vested and unvested expected to vest, December 31, 2014		901,882		$	6.28	8.9
Outstanding at December 31, 2014		906,194		$	6.29	9.0
Granted		1,194,871		$	2.07
Exercised	—			—
Cancelled/forfeited/expired		(46,727	)	$	4.33
Outstanding at September 30, 2015		2,054,338		$	3.88		9.1
Vested and unvested expected to vest, September 30, 2015		1,899,759		$	4.01		9.0

The intrinsic values of options outstanding and options vested and unvested expected to vest at September 30, 2015 were $313,095 and $287,631, respectively.

The fair values of option awards granted during the nine months ended September 30, 2015 were estimated using a Black-Scholes pricing model with the following assumptions:

Stock and exercise prices	$2.01 - $3.38
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	1.52% – 1.93%
Expected life (in years)	5.23 – 6.08
Expected volatility	70.0% – 100.0%

Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2015 was $1.35 per share.

On August 31, 2015, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $1.47 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors in its sole discretion, as follows:

	Percentage of
	Overall Stock
	Option Grant
	Subject to Vesting
Target
Minimum number of accessions processed, billed and collected in fiscal 2016		25	%
Minimum revenues from contracts with pharmaceutical companies in fiscal 2016		20	%
Attainment of a sustainable positive GAAP gross margin by December 31, 2016		25	%
Minimum operating cash on-hand at December 31, 2016, with no more than one interim dilutive equity financing event		30	%
Total		100	%

Further information about the options outstanding and exercisable at September 30, 2015 is as follows:

				Weighted
Weighted				Average
Average		Total Shares		Contractual		Total Shares
Exercise Price		Outstanding		Life (in years)		Exercisable
$	2.01		1,079,637		9.9		-
$	2.65		152,734		9.6		1,000
$	4.51		79,526		8.0		46,192
$	5.12		406,643		8.1		297,977
$	7.50		43,000		8.5		16,125
$	8.88		238,500		8.4		79,497
$	9.11		54,298		8.4		54,298
			2,054,338				495,089

The intrinsic value of options exercisable at September 30, 2015 was zero.

Restricted Stock

At September 30, 2015, there were 150,418 RSUs outstanding, of which 121,829 shares were vested and unvested expected to vest. The intrinsic values of RSUs outstanding and RSUs vested and unvested expected to vest at September 30, 2015 were $345,961 and $280,207, respectively.

Stock-based Compensation Expense

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented:

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2014		2015		2014		2015
Stock Options
Cost of revenues	$	-	$	15,029	$	-	$	48,839
Research and development expenses		35,569		20,910		149,626		65,835
General and administrative expenses		236,769		257,404		908,490		706,026
Sales and marketing expenses		27,834		31,888		46,762		93,989
Total expenses related to stock options		300,172		325,231		1,104,878		914,689
RSUs
Research and development expenses		7,500		1,625		22,500		10,724
General and administrative expenses		13,750		12,515		379,208		90,853
Total stock-based compensation	$	321,422	$	339,371	$	1,506,586	$	1,016,266

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 5% and 0% - 4% per annum during the three and nine months ended September 30, 2014 and 2015, respectively. As of September 30, 2015 total unrecognized stock-based compensation expense related to unvested stock option and RSU awards, adjusted for estimated forfeitures, was approximately $2,993,000 and $17,000, respectively, and is expected to be recognized over a weighted-average period of 2.7 years and 0.3 years, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Common Warrants Outstanding

9 Months Ended

Sep. 30, 2015

Other Liabilities Disclosure [Abstract]

Common Warrants Outstanding

8. Common Warrants Outstanding

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2015 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2014		609,187		$	9.93		3.8
Issued		9,200,000		$	1.56
Exercised		(6,216,449	)	$	1.56
Expired		(1,200,000	)	$	1.56
Outstanding at September 30, 2015		2,392,738		$	3.69		4.0

Further information about equity-classified common stock warrants outstanding and exercisable at September 30, 2015 is as follows:

				Weighted
Weighted				Average
Average		Total Shares		Contractual
Exercise Price		Outstanding		Life (in years)
$	1.56		1,783,551		4.4
$	4.72		52,966		8.6
$	10.00		461,221		2.4
$	12.50		95,000		3.4
			2,392,738

The intrinsic value of equity-classified common stock warrants outstanding and exercisable at September 30, 2015 was $1,319,828.

Net Loss per Common Share

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Net Loss per Common Share

9. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and nine months ended September 30, 2014 and 2015, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and nine months ended
	September 30,
	2014		2015
Preferred warrants outstanding (number of common stock equivalents)		1,587		1,587
Preferred share RSUs (number of common stock equivalents)		73,151		73,151
Common warrants outstanding		609,187		2,392,738
Common share RSUs		178,467		77,267
Common options outstanding		875,042		2,054,338
Total anti-dilutive common share equivalents		1,737,434		4,599,081

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. The Company’s former Vice President of Operations filed an administrative proceeding against the Company with the California Labor Commissioner in April 2013, seeking damages for alleged unpaid wages and penalties. A hearing was held on August 19, 2013 which resulted in a finding against the Company for approximately $65,000, of which $40,000 was paid during the year ended December 31, 2013 and $25,000 was accrued as of December 31, 2013. On February 25, 2014, the aforementioned administrative proceeding filed with the California Labor Commissioner by the Company’s former Vice President of Operations was settled in full following payment of the remaining $25,000 due.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Each of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for a total purchase price of $177,500 (see Note 2). Pursuant to a sublease agreement dated March 30, 2015, the Company rented 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc. (“Aegea”). On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement (the “Cross-License Agreement”) with Aegea. The Company received payments totaling $25,763 from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.